Cybin Gears Up for GMP Manufacturing of CYB003 Capsules for Phase 3 Study
Friday, August 18, 2023
Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) has revealed its initiation of preparations for producing a capsule variant of CYB003, their exclusive deuterated psilocybin analog. This advancement marks a significant stride in the company's mission to transform mental healthcare through the development of groundbreaking psychedelic-centered treatments. The primary focus of this endeavor is the potential treatment of Major Depressive Disorder (MDD).
The company's endeavors have resulted in the creation of a robust solid-dosage capsule iteration of CYB003. This capsule has been meticulously designed to offer stability, dosing flexibility, patient convenience, and scalability to potentially support commercial production. The forthcoming Phase 3 trial aims to assess the efficacy of this newly formulated capsule. The ongoing Phase 2 MDD study is presently administering CYB003 dosages within its final cohort. Anticipated in the third or fourth quarter of 2023, the top-line results are expected to demonstrate the compound's effectiveness. Following this, the company's plan involves presenting this data to the U.S. Food and Drug Administration (FDA) as part of an end-of-Phase-2 meeting.
Doug Drysdale, the Chief Executive Officer of Cybin, has expressed his enthusiasm for this breakthrough. He highlights that the capsule formulation signifies a significant leap towards a more convenient and commercially viable dosing alternative, potentially suitable for future Phase 3 trials. Drysdale also underscores the remarkable progress achieved by the CYB003 program in addressing MDD, underscoring the company's dedication to enhancing treatment options for individuals grappling with major depressive disorder. Additionally, he acknowledges the strategic collaboration with Worldwide Clinical Trials, a prominent Contract Research Organization (CRO) specialized in psychedelic clinical trials. The development of EMBARKCT, a scalable model tailored for Cybin's psychedelic facilitation program, further underscores the company's achievements, showcasing its adeptness in executing clinical strategies throughout its developmental journey.
